BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 24707941)

  • 1. Autologous transplant for relapsed follicular lymphoma: impact of pre-transplant rituximab sensitivity.
    Phipps C; Gopal AK; Storer BE; Cassaday RD; Press OW; Till BG; Pagel JM; Palanca-Wessels MC; Philip M; Bensinger WI; Holmberg LA; Shustov AR; Green DJ; Chauncey T; Maloney DG; Libby EN
    Leuk Lymphoma; 2015 Jan; 56(1):92-6. PubMed ID: 24707941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults.
    Schaaf M; Reiser M; Borchmann P; Engert A; Skoetz N
    Cochrane Database Syst Rev; 2012 Jan; 1():CD007678. PubMed ID: 22258971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical characteristics and outcomes of relapsed follicular lymphoma after autologous stem cell transplantation in the rituximab era.
    Sesques P; Bourcier J; Golfier C; Lebras L; Nicolas-Virelizier E; Hacini M; Perrin MC; Voillat L; Bachy E; Traverse-Glehen A; Moreau A; Martin L; Ramla S; Casasnovas O; Le Gouill S; Salles G; Ghesquières H
    Hematol Oncol; 2020 Apr; 38(2):137-145. PubMed ID: 31953963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Durable event-free survival following autologous stem cell transplant for relapsed or refractory follicular lymphoma: positive impact of recent rituximab exposure and low-risk Follicular Lymphoma International Prognostic Index score.
    Peters AC; Duan Q; Russell JA; Duggan P; Owen C; Stewart DA
    Leuk Lymphoma; 2011 Nov; 52(11):2124-9. PubMed ID: 21740097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors.
    Klyuchnikov E; Bacher U; Kröger NM; Hari PN; Ahn KW; Carreras J; Bachanova V; Bashey A; Cohen JB; D'Souza A; Freytes CO; Gale RP; Ganguly S; Hertzberg MS; Holmberg LA; Kharfan-Dabaja MA; Klein A; Ku GH; Laport GG; Lazarus HM; Miller AM; Mussetti A; Olsson RF; Slavin S; Usmani SZ; Vij R; Wood WA; Maloney DG; Sureda AM; Smith SM; Hamadani M
    Biol Blood Marrow Transplant; 2015 Dec; 21(12):2091-2099. PubMed ID: 26253007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autologous hematopoietic stem cell transplantation for relapsed follicular lymphoma: safety profile and clinical outcome in a single-center experience.
    Helbig G; Krawczyk-Kulis M; Kopinska A; Liwoch R; Kyrcz-Krzemien S
    Med Oncol; 2014 Dec; 31(12):310. PubMed ID: 25373321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab purging and/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: a prospective randomized trial from the lymphoma working party of the European group for blood and marrow transplantation.
    Pettengell R; Schmitz N; Gisselbrecht C; Smith G; Patton WN; Metzner B; Caballero D; Tilly H; Walewski JA; Bence-Bruckler I; To B; Geisler CH; Schots R; Kimby E; Taverna CJ; Kozák T; Dreger P; Uddin R; Ruiz de Elvira C; Goldstone AH
    J Clin Oncol; 2013 May; 31(13):1624-30. PubMed ID: 23547078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prolonged clinical remissions in patients with relapsed or refractory follicular lymphoma treated with autologous stem cell transplantation incorporating rituximab.
    Berinstein NL; Bhella S; Pennell NM; Cheung MC; Imrie KR; Spaner DE; Milliken V; Zhang L; Hewitt K; Boudreau A; Reis MD; Chesney A; Good D; Ghorab Z; Hicks LK; Piliotis E; Buckstein R
    Ann Hematol; 2015 May; 94(5):813-23. PubMed ID: 25567231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab: a comprehensive analysis from the NCCN lymphoma outcomes project.
    Evens AM; Vanderplas A; LaCasce AS; Crosby AL; Nademanee AP; Kaminski MS; Abel GA; Millenson M; Czuczman MS; Rodriguez MA; Niland J; Zelenetz AD; Gordon LI; Friedberg JW
    Cancer; 2013 Oct; 119(20):3662-71. PubMed ID: 23921646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autologous stem cell transplantation for follicular lymphoma is of most benefit early in the disease course and can result in durable remissions, irrespective of prior rituximab exposure.
    Kothari J; Peggs KS; Bird A; Thomson KJ; Morris E; Virchis AE; Lambert J; Goldstone AH; Linch DC; Ardeshna KM
    Br J Haematol; 2014 May; 165(3):334-40. PubMed ID: 24438080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab maintenance after autologous stem cell transplantation prolongs response duration in non-naive rituximab follicular lymphoma patients: a single institution experience.
    Bourcier J; Gastinne T; Leux C; Moreau A; Bossard C; Mahé B; Blin N; Dubruille V; Touzeau C; Voldoire M; Guillaume T; Peterlin P; Gallas P; Garnier A; Maisonneuve H; Moreau P; Juge-Morineau N; Jardel H; Chevallier P; Moreau P; Le Gouill S
    Ann Hematol; 2016 Aug; 95(8):1287-93. PubMed ID: 27297970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autologous Stem Cell Transplantation for Follicular Lymphoma: Favorable Long-Term Survival Irrespective of Pretransplantation Rituximab Exposure.
    Jiménez-Ubieto A; Grande C; Caballero D; Yáñez L; Novelli S; Hernández-Garcia MT; Manzanares M; Arranz R; Ferreiro JJ; Bobillo S; Mercadal S; Galeo A; López Jiménez J; Moraleda JM; Vallejo C; Albo C; Pérez E; Marrero C; Magnano L; Palomera L; Jarque I; Martínez-Sánchez P; Martín A; Coria E; López-Guillermo A; Salar A; Lahuerta JJ
    Biol Blood Marrow Transplant; 2017 Oct; 23(10):1631-1640. PubMed ID: 28533060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of the use of autologous stem cell transplantation at first relapse both in naive and previously rituximab exposed follicular lymphoma patients treated in the GELA/GOELAMS FL2000 study.
    Le Gouill S; De Guibert S; Planche L; Brice P; Dupuis J; Cartron G; Van Hoof A; Casasnovas O; Gyan E; Tilly H; Fruchart C; Deconinck E; Fitoussi O; Gastaud L; Delwail V; Gabarre J; Gressin R; Blanc M; Foussard C; Salles G;
    Haematologica; 2011 Aug; 96(8):1128-35. PubMed ID: 21486862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A 15-year analysis of early and late autologous hematopoietic stem cell transplant in relapsed, aggressive, transformed, and nontransformed follicular lymphoma.
    Sabloff M; Atkins HL; Bence-Bruckler I; Bredeson C; Fergusson D; Genest P; Hopkins H; Hutton B; Mcdiarmid S; Huebsch LB
    Biol Blood Marrow Transplant; 2007 Aug; 13(8):956-64. PubMed ID: 17640600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autologous transplant of follicular lymphoma in the era of rituximab.
    Witzens-Harig M; Dreger P
    Leuk Lymphoma; 2010 Jun; 51(6):967-74. PubMed ID: 20443675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autologous and allogeneic stem-cell transplantation for transformed follicular lymphoma: a report of the Canadian blood and marrow transplant group.
    Villa D; Crump M; Panzarella T; Savage KJ; Toze CL; Stewart DA; MacDonald DA; Buckstein R; Lee C; Alzahrani M; Rubinger M; Foley R; Xenocostas A; Sabloff M; Muccilli A; Chua N; Couture F; Larouche JF; Cohen S; Connors JM; Ambler K; Al-Tourah A; Ramadan KM; Kuruvilla J
    J Clin Oncol; 2013 Mar; 31(9):1164-71. PubMed ID: 23401459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study.
    Brugger W; Hirsch J; Grünebach F; Repp R; Brossart P; Vogel W; Kopp HG; Manz MG; Bitzer M; Schlimok G; Kaufmann M; Ganser A; Fehnle K; Gramatzki M; Kanz L
    Ann Oncol; 2004 Nov; 15(11):1691-8. PubMed ID: 15520073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of prior rituximab on outcomes of autologous stem-cell transplantation in patients with relapsed or refractory aggressive B-cell lymphoma: a multicentre retrospective Spanish group of lymphoma/autologous bone marrow transplant study.
    Redondo AM; Pomares H; Vidal MJ; Pascual MJ; Quereda B; Sancho JM; Polo M; López J; Conde E; Jarque I; Alonso N; Ramírez MJ; Fernández P; Sayas MJ; Requena MJ; Salar A; González JD; González-Barca E; Arranz R; Caballero D; Martín A
    Br J Haematol; 2014 Mar; 164(5):668-74. PubMed ID: 24274082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autologous stem cell transplantation with in vivo purged progenitor cells shows long-term efficacy in relapsed/refractory follicular lymphoma.
    Arcaini L; Morello L; Tucci A; Rusconi C; Ladetto M; Rattotti S; Bonfichi M; Bottelli C; Gabutti C; Bernasconi P; Varettoni M; Gotti M; Troletti D; Guerrera ML; Fiaccadori V; Sciarra R; Ferretti VV; Alessandrino EP; Rossi G; Morra E
    Am J Hematol; 2015 Mar; 90(3):230-4. PubMed ID: 25502635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Durable benefit of rituximab maintenance post-autograft in patients with relapsed follicular lymphoma: 12-year follow-up of the EBMT lymphoma working party Lym1 trial.
    Pettengell R; Uddin R; Boumendil A; Johnson R; Metzner B; Martín A; Romejko-Jarosinska J; Bence-Bruckler I; Giri P; Niemann CU; Robinson SP; Kimby E; Schmitz N; Dreger P; Goldstone AH; Montoto S
    Bone Marrow Transplant; 2021 Jun; 56(6):1413-1421. PubMed ID: 33452448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.